Get started
Author

Qianting Zhai

ORCID: 0000-0002-1597-7119
Observed ORCID: 0000-0002-1597-7119
OpenAlex ID: A5109131122
Alternative molecular formats and therapeutic applications for bispecific antibodies
2015 · Christoph Spiess, Qianting Zhai, et al. · Molecular Immunology · 638
PDF
Structural and Biochemical Studies of ALIX/AIP1 and Its Role in Retrovirus Budding
2007 · Robert D. Fisher, Hyo-Young Chung, et al. · Cell · 336
PDF
Structural and functional studies of ALIX interactions with YPXnL late domains of HIV-1 and EIAV
2007 · Qianting Zhai, Robert D Fisher, et al. · Nature Structural & Molecular Biology · 156
Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations
2010 · Heidi L. Schubert, Qianting Zhai, et al. · Proceedings of the National Academy of Sciences · 102
Activation of the Retroviral Budding Factor ALIX
2011 · Qianting Zhai, Michael B. Landesman, et al. · Journal of Virology · 54
Identification and Structural Characterization of the ALIX-Binding Late Domains of Simian Immunodeficiency Virus SIV mac239 and SIV agmTan-1
2010 · Qianting Zhai, Michael B. Landesman, et al. · Journal of Virology · 52
Structure of the Bro1 Domain Protein BROX and Functional Analyses of the ALIX Bro1 Domain in HIV-1 Budding
2011 · Qianting Zhai, Michael B. Landesman, et al. · PLoS ONE · 31
PDF
Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al. · Cancer Research · 12
Structural Analysis and Optimization of Context-Independent Anti-Hypusine Antibodies
2016 · Qianting Zhai, Meng He, et al. · Journal of Molecular Biology · 12
PDF
Successful targeting of multidrug-resistant tumors with bispecific antibodies
2025 · Raffaella Briante, Qianting Zhai, et al. · mAbs · 5
282 Bispecific antibodies (BsAbs) targeting ABCB1/PgP and CD47 provide a multi-modal, tumor specific approach to combat drug resistant cancers
2021 · Robert Arathoon, Raffaella Briante, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Key resources table from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al. · 1
Figure S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Figure S3 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Table S1 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Figure S5 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Figure S1 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Table S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Figure S7 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Table S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Data from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Table S5 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Table S3 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Figure S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Figure S6 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
2026 · Lu Qi, Guohui Dang, et al.
Works count: 26
Citation count: 1,401
H-index: 9
I10-index: 9
Year
Topic
Type